PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES

• Kim Linton,
• Jeanette Doorduijn,
• Dima El-Sharkawi,
• Rogier Mous,
• Francesco Forconi,
• David Lewis,
• Mary Gleeson,
• John Riches,
• Pam Mckay,
• Wendy Stevens,
• Sarah G Injac,
• Graham P Collins

Affiliations

Kim Linton

1 Manchester Cancer Research Centre, Division of Cancer Sciences, Manchester, United Kingdom

Jeanette Doorduijn

2 Erasmus MC Cancer Institute, on behalf of the Lunenburg Lymphoma Phase I/II Consortium – HOVON/LLPC, Rotterdam, The Netherlands

Dima El-Sharkawi

3 Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Rogier Mous

4 UMC Utrecht Cancer Center, University Medical Center Utrecht, on behalf of the Lunenburg Lymphoma Phase I/II Consortium – HOVON/LLPC, Utrecht, The Netherlands

Francesco Forconi

5 University Hospital Southampton NHS Trust, Southampton, United Kingdom

David Lewis

6 Derriford Hospital, Plymouth, United Kingdom

Mary Gleeson

7 Sarah Cannon Research Institute, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

John Riches

8 Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Pam Mckay

9 Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

Wendy Stevens

10 Radboud University Medical Center, on behalf of the Lunenburg Lymphoma Phase I/II Consortium – HOVON/LLPC, Nijmegen, The Netherlands

Sarah G Injac

11 Nurix Therapeutics, Inc., San Francisco, United States

Graham P Collins

12 Oxford University Hospitals Foundation NHS Trust,, Oxford, United Kingdom